PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Eslicarbazepine acetate - Epilepsy

PAD Profile : Eslicarbazepine acetate - Epilepsy Important

Brand Names Include :
Zebinix
Important Information :
Only when 1st-line and 1st-line adjunctive agents have been unsuccessful

Traffic Light Status

Status 1 of 1.

Status :
Amber
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
20 February 2013
Epsom St Helier NDAIG
Shared care documentation approved
04 April 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The PCN supported the principles of switching from brand to generic medications (not recommended in the elderly) as per national guidelines in September 2013 and the proposed place in therapy of the anti-epileptic drugs which is based on NICE guidance was also discussed at that time. Shared Care supported in November 2014 are attached below. Please note the MHRA categorisations for each drug in the attached guidance (updated January 2014) and in the link below.

Associated BNF Codes

04. Central Nervous System
04.08.01. Control of epilepsy
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More